SWP
ABBV icon

ShoreHaven Wealth Partners’s AbbVie ABBV Stock Holding History

ShoreHaven Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-318
Closed -$35K – 54
2021
Q1 		$35K Buy
318
+191
+150% +$20.4K 0.02% 137
2020
Q4 		$14K Buy
+127
New +$12.2K 0.01% 161

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

ShoreHaven Wealth Partners's ABBV Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of AbbVie (ABBV) in Q2 2021, closing a stake of 318 shares — an estimated $35K sold.

ShoreHaven Wealth Partners first reported a position in ABBV in Q4 2020 and held it in 2 quarters. The position peaked at $35K in Q1 2021. 2,677 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

  • ShoreHaven Wealth Partners reported no remaining AbbVie position as of Q2 2021 after selling out during the quarter.
  • ShoreHaven Wealth Partners sold 318 AbbVie shares in Q2 2021, an estimated $35K.
  • ShoreHaven Wealth Partners first reported a position in AbbVie in Q4 2020 and held it in 2 quarters.
  • ShoreHaven Wealth Partners's AbbVie position peaked at $35K in Q1 2021.
  • 2,677 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.